|
JPH10130258A
(ja)
*
|
1996-10-10 |
1998-05-19 |
Eli Lilly & Co |
ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
|
|
AU7170798A
(en)
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
WO1998048804A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
AU7170898A
(en)
*
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
ES2223129T3
(es)
|
1997-04-30 |
2005-02-16 |
Eli Lilly And Company |
Agentes antitromboticos.
|
|
JP2002513415A
(ja)
|
1997-04-30 |
2002-05-08 |
イーライ・リリー・アンド・カンパニー |
抗血栓剤
|
|
WO1998048800A1
(en)
|
1997-05-01 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
EP0988289A2
(en)
*
|
1997-06-05 |
2000-03-29 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds, their production and use
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
ES2189355T3
(es)
*
|
1998-10-28 |
2003-07-01 |
Lilly Co Eli |
Compuestos de benzotiofeno como agentes antitromboticos e intermedios.
|
|
ES2213984T3
(es)
|
1998-10-30 |
2004-09-01 |
Eli Lilly And Company |
Derivados de azaindol y su uso como agentes antitrombicos.
|
|
AU1434201A
(en)
*
|
1999-11-19 |
2001-05-30 |
Eli Lilly And Company |
Antithrombotic agents
|
|
DE60210283T2
(de)
|
2001-05-22 |
2006-11-09 |
Eli Lilly And Co., Indianapolis |
2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
|
|
DE60202954T2
(de)
|
2001-05-22 |
2006-01-05 |
Eli Lilly And Co., Indianapolis |
Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
WO2003059884A1
(en)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulators of lxr
|
|
CA2490580C
(en)
*
|
2002-07-22 |
2012-12-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators containing a naphthalene group
|
|
US7296361B2
(en)
*
|
2003-07-31 |
2007-11-20 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
CN104109155A
(zh)
|
2003-08-01 |
2014-10-22 |
田边三菱制药株式会社 |
新颖化合物
|
|
US8278290B2
(en)
|
2005-02-14 |
2012-10-02 |
Biononics Limited |
Tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
ME03072B
(me)
|
2007-09-10 |
2019-01-20 |
Janssen Pharmaceutica Nv |
Postupak za dobijanje jedinjenja која su korisna као inhibiтori sgl т
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
CN102648196B
(zh)
|
2009-10-14 |
2016-04-27 |
詹森药业有限公司 |
可用作sglt2的抑制剂的化合物的制备方法
|
|
MX339570B
(es)
|
2010-05-11 |
2016-05-31 |
Janssen Pharmaceutica Nv |
Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
|
|
EA028946B1
(ru)
|
2011-04-13 |
2018-01-31 |
Янссен Фармацевтика Нв |
Способ получения соединений для применения в качестве ингибиторов sglt2
|
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
EP2791143B1
(en)
|
2011-12-15 |
2016-02-24 |
Bayer Intellectual Property GmbH |
Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
|
|
US9475815B2
(en)
|
2012-02-23 |
2016-10-25 |
Bayer Intelletual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
|
JP6508324B2
(ja)
*
|
2015-02-19 |
2019-05-08 |
Jnc株式会社 |
ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
EP3464272B1
(en)
|
2016-06-07 |
2021-12-08 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
AU2018239542C1
(en)
|
2017-03-23 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as SHP2 inhibitors
|
